Copyright Reports & Markets. All rights reserved.

Global Interleukin Inhibitors for the Treatment of Refractory Gout Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Interleukin Inhibitors for the Treatment of Refractory Gout Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Canakinumab
    • 1.3.3 Anakinra
    • 1.3.4 Tocilizumab
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Interleukin Inhibitors for the Treatment of Refractory Gout Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital and Clinic
    • 1.4.3 Retail Pharmacies
    • 1.4.4 Other
  • 1.5 Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Size & Forecast
    • 1.5.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity (2021-2032)
    • 1.5.3 Global Interleukin Inhibitors for the Treatment of Refractory Gout Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Novartis
    • 2.1.1 Novartis Details
    • 2.1.2 Novartis Major Business
    • 2.1.3 Novartis Interleukin Inhibitors for the Treatment of Refractory Gout Product and Services
    • 2.1.4 Novartis Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Novartis Recent Developments/Updates
  • 2.2 Sobi
    • 2.2.1 Sobi Details
    • 2.2.2 Sobi Major Business
    • 2.2.3 Sobi Interleukin Inhibitors for the Treatment of Refractory Gout Product and Services
    • 2.2.4 Sobi Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Sobi Recent Developments/Updates
  • 2.3 Roche
    • 2.3.1 Roche Details
    • 2.3.2 Roche Major Business
    • 2.3.3 Roche Interleukin Inhibitors for the Treatment of Refractory Gout Product and Services
    • 2.3.4 Roche Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Roche Recent Developments/Updates
  • 2.4 Biogen
    • 2.4.1 Biogen Details
    • 2.4.2 Biogen Major Business
    • 2.4.3 Biogen Interleukin Inhibitors for the Treatment of Refractory Gout Product and Services
    • 2.4.4 Biogen Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Biogen Recent Developments/Updates
  • 2.5 Fresenius Kabi
    • 2.5.1 Fresenius Kabi Details
    • 2.5.2 Fresenius Kabi Major Business
    • 2.5.3 Fresenius Kabi Interleukin Inhibitors for the Treatment of Refractory Gout Product and Services
    • 2.5.4 Fresenius Kabi Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Fresenius Kabi Recent Developments/Updates
  • 2.6 Hetero
    • 2.6.1 Hetero Details
    • 2.6.2 Hetero Major Business
    • 2.6.3 Hetero Interleukin Inhibitors for the Treatment of Refractory Gout Product and Services
    • 2.6.4 Hetero Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Hetero Recent Developments/Updates
  • 2.7 Bio-Thera Solutions
    • 2.7.1 Bio-Thera Solutions Details
    • 2.7.2 Bio-Thera Solutions Major Business
    • 2.7.3 Bio-Thera Solutions Interleukin Inhibitors for the Treatment of Refractory Gout Product and Services
    • 2.7.4 Bio-Thera Solutions Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Bio-Thera Solutions Recent Developments/Updates
  • 2.8 Zhuhai Livzon Biotechnology
    • 2.8.1 Zhuhai Livzon Biotechnology Details
    • 2.8.2 Zhuhai Livzon Biotechnology Major Business
    • 2.8.3 Zhuhai Livzon Biotechnology Interleukin Inhibitors for the Treatment of Refractory Gout Product and Services
    • 2.8.4 Zhuhai Livzon Biotechnology Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Zhuhai Livzon Biotechnology Recent Developments/Updates
  • 2.9 Hangzhou Bozhirui Biopharmaceutical
    • 2.9.1 Hangzhou Bozhirui Biopharmaceutical Details
    • 2.9.2 Hangzhou Bozhirui Biopharmaceutical Major Business
    • 2.9.3 Hangzhou Bozhirui Biopharmaceutical Interleukin Inhibitors for the Treatment of Refractory Gout Product and Services
    • 2.9.4 Hangzhou Bozhirui Biopharmaceutical Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Hangzhou Bozhirui Biopharmaceutical Recent Developments/Updates

3 Competitive Environment: Interleukin Inhibitors for the Treatment of Refractory Gout by Manufacturer

  • 3.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Manufacturer (2021-2026)
  • 3.3 Global Interleukin Inhibitors for the Treatment of Refractory Gout Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Interleukin Inhibitors for the Treatment of Refractory Gout by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Interleukin Inhibitors for the Treatment of Refractory Gout Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Interleukin Inhibitors for the Treatment of Refractory Gout Manufacturer Market Share in 2025
  • 3.5 Interleukin Inhibitors for the Treatment of Refractory Gout Market: Overall Company Footprint Analysis
    • 3.5.1 Interleukin Inhibitors for the Treatment of Refractory Gout Market: Region Footprint
    • 3.5.2 Interleukin Inhibitors for the Treatment of Refractory Gout Market: Company Product Type Footprint
    • 3.5.3 Interleukin Inhibitors for the Treatment of Refractory Gout Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Size by Region
    • 4.1.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Interleukin Inhibitors for the Treatment of Refractory Gout Consumption Value by Region (2021-2032)
    • 4.1.3 Global Interleukin Inhibitors for the Treatment of Refractory Gout Average Price by Region (2021-2032)
  • 4.2 North America Interleukin Inhibitors for the Treatment of Refractory Gout Consumption Value (2021-2032)
  • 4.3 Europe Interleukin Inhibitors for the Treatment of Refractory Gout Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Consumption Value (2021-2032)
  • 4.5 South America Interleukin Inhibitors for the Treatment of Refractory Gout Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Interleukin Inhibitors for the Treatment of Refractory Gout Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity by Type (2021-2032)
  • 5.2 Global Interleukin Inhibitors for the Treatment of Refractory Gout Consumption Value by Type (2021-2032)
  • 5.3 Global Interleukin Inhibitors for the Treatment of Refractory Gout Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity by Application (2021-2032)
  • 6.2 Global Interleukin Inhibitors for the Treatment of Refractory Gout Consumption Value by Application (2021-2032)
  • 6.3 Global Interleukin Inhibitors for the Treatment of Refractory Gout Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity by Type (2021-2032)
  • 7.2 North America Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity by Application (2021-2032)
  • 7.3 North America Interleukin Inhibitors for the Treatment of Refractory Gout Market Size by Country
    • 7.3.1 North America Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Interleukin Inhibitors for the Treatment of Refractory Gout Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity by Type (2021-2032)
  • 8.2 Europe Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity by Application (2021-2032)
  • 8.3 Europe Interleukin Inhibitors for the Treatment of Refractory Gout Market Size by Country
    • 8.3.1 Europe Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Interleukin Inhibitors for the Treatment of Refractory Gout Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Market Size by Region
    • 9.3.1 Asia-Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity by Type (2021-2032)
  • 10.2 South America Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity by Application (2021-2032)
  • 10.3 South America Interleukin Inhibitors for the Treatment of Refractory Gout Market Size by Country
    • 10.3.1 South America Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Interleukin Inhibitors for the Treatment of Refractory Gout Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Interleukin Inhibitors for the Treatment of Refractory Gout Market Size by Country
    • 11.3.1 Middle East & Africa Interleukin Inhibitors for the Treatment of Refractory Gout Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Interleukin Inhibitors for the Treatment of Refractory Gout Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Interleukin Inhibitors for the Treatment of Refractory Gout Market Drivers
  • 12.2 Interleukin Inhibitors for the Treatment of Refractory Gout Market Restraints
  • 12.3 Interleukin Inhibitors for the Treatment of Refractory Gout Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Interleukin Inhibitors for the Treatment of Refractory Gout and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Interleukin Inhibitors for the Treatment of Refractory Gout
  • 13.3 Interleukin Inhibitors for the Treatment of Refractory Gout Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Interleukin Inhibitors for the Treatment of Refractory Gout Typical Distributors
  • 14.3 Interleukin Inhibitors for the Treatment of Refractory Gout Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Interleukin Inhibitors for the Treatment of Refractory Gout market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    Interleukin inhibitors represent a promising therapeutic approach for the treatment of refractory gout.By blocking these interleukins,such as IL-1β and IL-6,these biologic drugs can effectively reduce inflammation and alleviate symptoms in patients who do not respond adequately to conventional therapies like nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids.
    This report is a detailed and comprehensive analysis for global Interleukin Inhibitors for the Treatment of Refractory Gout market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Interleukin Inhibitors for the Treatment of Refractory Gout market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Interleukin Inhibitors for the Treatment of Refractory Gout market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Interleukin Inhibitors for the Treatment of Refractory Gout market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Interleukin Inhibitors for the Treatment of Refractory Gout market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Interleukin Inhibitors for the Treatment of Refractory Gout
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Interleukin Inhibitors for the Treatment of Refractory Gout market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Sobi, Roche, Biogen, Fresenius Kabi, Hetero, Bio-Thera Solutions, Zhuhai Livzon Biotechnology, Hangzhou Bozhirui Biopharmaceutical, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Interleukin Inhibitors for the Treatment of Refractory Gout market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Canakinumab
    Anakinra
    Tocilizumab
    Market segment by Application
    Hospital and Clinic
    Retail Pharmacies
    Other
    Major players covered
    Novartis
    Sobi
    Roche
    Biogen
    Fresenius Kabi
    Hetero
    Bio-Thera Solutions
    Zhuhai Livzon Biotechnology
    Hangzhou Bozhirui Biopharmaceutical
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Interleukin Inhibitors for the Treatment of Refractory Gout product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Interleukin Inhibitors for the Treatment of Refractory Gout, with price, sales quantity, revenue, and global market share of Interleukin Inhibitors for the Treatment of Refractory Gout from 2021 to 2026.
    Chapter 3, the Interleukin Inhibitors for the Treatment of Refractory Gout competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Interleukin Inhibitors for the Treatment of Refractory Gout breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Interleukin Inhibitors for the Treatment of Refractory Gout market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Interleukin Inhibitors for the Treatment of Refractory Gout.
    Chapter 14 and 15, to describe Interleukin Inhibitors for the Treatment of Refractory Gout sales channel, distributors, customers, research findings and conclusion.

    Buy now